Journal of Antimicrobial Chemotherapy (2000) 45, 35
© 2000 The British Society for Antimicrobial Chemotherapy
Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review
Division of Infectious Diseases, Department of Pediatrics, SUNY Health Science Center at Brooklyn, Brooklyn, NY 11203-2098, USA
Quinolones are currently used as empirical therapy for treatment of community-acquired lower respiratory infections as they are effective against a broad range of conventional bacterial and ‘atypical’ pathogens, including Chlamydia pneumoniae. C. pneumoniae is estimated to be associated with 10–20% of community-acquired pneumonia in adults, and has recently been suggested to play a role in several non-respiratory conditions, including atherosclerosis. The newer, third-generation quinolones have enhanced activity against Gram-positive bacteria, including Streptococcus pneumoniae, and prolonged serum half-lives that permit once-daily dosing. Although gemifloxacin (SB-265805) and other new quinolones have good activity against C. pneumoniae in vitro, practically all published treatment studies have relied on serological diagnosis. Consequently, the microbiological efficacy of these agents in human infection has not been assessed. This paper reviews what is known to date of the in vivo microbiological efficacy of the quinolones against C. pneumoniae, and demonstrates the importance of assessing this parameter when evaluating the clinical utility of these agents in C. pneumoniae infection.
* Correspondence address. 450 Clarkson Avenue, Box 49, Brooklyn, NY 11203-2098, USA. Tel: +1-718-245-4075; Fax: +1-718-245-2118; E-mail: mhammerschlag{at}pol.net
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Petrovay and E. Balla Two fatal cases of psittacosis caused by Chlamydophila psittaci J. Med. Microbiol., October 1, 2008; 57(10): 1296 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Hammerschlag Comment on: Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study J. Antimicrob. Chemother., October 1, 2007; 60(4): 902 - 903. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Johnston and R. J. Martin Chlamydophila pneumoniae and Mycoplasma pneumoniae: A Role in Asthma Pathogenesis? Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1078 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Willemsen, C. Ronteltap, P. Chames, R. Debets, and R. L. H. Bolhuis T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine Production J. Immunol., June 15, 2005; 174(12): 7853 - 7858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kasbekar and P. S. Acharya Telithromycin: The first ketolide for the treatment of respiratory infections Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yang and D. Baltimore Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells PNAS, March 22, 2005; 102(12): 4518 - 4523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Morello, M. Ye, S. Hung, L. A. Kelley, and D. H. Spector Systemic Priming-Boosting Immunization with a Trivalent Plasmid DNA and Inactivated Murine Cytomegalovirus (MCMV) Vaccine Provides Long-Term Protection against Viral Replication following Systemic or Mucosal MCMV Challenge J. Virol., January 1, 2005; 79(1): 159 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Inobe and R. H. Schwartz CTLA-4 Engagement Acts as a Brake on CD4+ T Cell Proliferation and Cytokine Production but Is Not Required for Tuning T Cell Reactivity in Adaptive Tolerance J. Immunol., December 15, 2004; 173(12): 7239 - 7248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. K. Stevenson, C. H. Ottensmeier, P. Johnson, D. Zhu, S. L. Buchan, K. J. McCann, J. S. Roddick, A. T. King, F. McNicholl, N. Savelyeva, et al. DNA vaccines to attack cancer PNAS, October 5, 2004; 101(suppl_2): 14646 - 14652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tormakangas, H. Alakarppa, D. B. David, M. Leinonen, and P. Saikku Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3655 - 3661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Hammerschlag and P. M. Roblin The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae J. Antimicrob. Chemother., July 1, 2004; 54(1): 281 - 282. [Full Text] [PDF]
|
|
|
|
|
|
R. P. Smith, A. L. Baltch, W. J. Ritz, A. N. Carpenter, T. A. Halse, and L. H. Bopp In Vitro Activities of Garenoxacin and Levofloxacin against Chlamydia pneumoniae Are Not Affected by Presence of Mycoplasma DNA Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2081 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Baldanti, D. Lilleri, G. Campanini, G. Comolli, A. L. Ridolfo, S. Rusconi, and G. Gerna Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response J. Antimicrob. Chemother., March 1, 2004; 53(3): 536 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Tu, S. Chen, M. Sharp, C. Dekker, A. M. Manganello, E. C. Tongson, H. T. Maecker, T. H. Holmes, Z. Wang, G. Kemble, et al. Persistent and Selective Deficiency of CD4+ T Cell Immunity to Cytomegalovirus in Immunocompetent Young Children J. Immunol., March 1, 2004; 172(5): 3260 - 3267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Muthukumar, A. Wozniakowski, M.-C. Gauduin, M. Paiardini, H. M. McClure, R. P. Johnson, G. Silvestri, and D. L. Sodora Elevated interleukin-7 levels not sufficient to maintain T-cell homeostasis during simian immunodeficiency virus-induced disease progression Blood, February 1, 2004; 103(3): 973 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Jenkins, D. T. Rowe, and C. R. Rinaldo Jr. Herpesvirus Infections in Organ Transplant Recipients Clin. Vaccine Immunol., January 1, 2003; 10(1): 1 - 7. [Full Text] [PDF]
|
|
|
|
|
|
A. Kutlin, P. M. Roblin, and M. R. Hammerschlag Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model J. Antimicrob. Chemother., May 1, 2002; 49(5): 763 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Malay, P. M. Roblin, T. Reznik, A. Kutlin, and M. R. Hammerschlag In Vitro Activities of BMS-284756 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae Antimicrob. Agents Chemother., February 1, 2002; 46(2): 517 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Villinger, G. T. Brice, A. E. Mayne, P. Bostik, K. Mori, C. H. June, and A. A. Ansari Adoptive transfer of simian immunodeficiency virus (SIV) naive autologous CD4+ cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status Blood, January 15, 2002; 99(2): 590 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Boman and M. R. Hammerschlag Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies Clin. Microbiol. Rev., January 1, 2002; 15(1): 1 - 20. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Hammerschlag Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin J. Antimicrob. Chemother., November 1, 2001; 48(5): 735 - 735. [Full Text] [PDF]
|
|
|
|
|
|
T. M. File Jr, B. Schlemmer, J. Garau, M. Cupo, C. Young, and the 049 Clinical Study Group Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin J. Antimicrob. Chemother., July 1, 2001; 48(1): 67 - 74. [Abstract] [Full Text] [PDF]
|
|